A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92.

View in: PubMed

subject areas

Antineoplastic Agents
Chicago
Diarrhea
Early Termination of Clinical Trials
Fatigue
Humans
Indazoles
Male
Orchiectomy
Patient Compliance
Prostatic Neoplasms
Pyrimidines
Sulfonamides
Treatment Outcome
United States
United States Department of Defense
Universities

authors with profiles

Peter H. O'Donnell
Russell Z. Szmulewitz
Daniel H. Shevrin
Walter M. Stadler
Theodore Karrison